...
首页> 外文期刊>Bioanalysis >Development of an UPLC-MS/MS micromethod for quantitation of cinitapride in plasma and its application in a pharmacokinetic interaction trial
【24h】

Development of an UPLC-MS/MS micromethod for quantitation of cinitapride in plasma and its application in a pharmacokinetic interaction trial

机译:UPLC-MS / MS Micromethod的研制,用于定量血浆中菌癌及其在药代动力学相互作用试验中的应用

获取原文
获取原文并翻译 | 示例
           

摘要

Aim: Cinitapride (CIN) is a benzamide-derived molecule used for the treatment of gastroesophageal reflux and dyspepsia. Its pharmacokinetics are controversial due to the use of supratherapeutic doses and the lack of sensitive methodology. Therefore, a sensitive and accurate micromethod was developed for its quantitation in human plasma. Results: CIN was extracted from 300 mu l of heparinized plasma by liquid-liquid extraction using cisapride as internal standard, and analyzed with an ultra performance liquid chromatograph employing positive multiple-reaction monitoring-MS. Conclusion: The method proved to be rapid, accurate and stable within a range between 50 and 2000 pg/ml and was successfully validated and applied in a pharmacokinetic interaction trial, where it was demonstrated that oral co-administration of simethicone does not modify the bioavailability of CIN.
机译:目的:Cinitapride(Cin)是用于治疗胃食管反流和消化不良的苯胺衍生的分子。 其药代动力学由于使用SuprattaElecutic剂量和缺乏敏感方法而存在争议。 因此,为其在人血浆中的定量开发了一种敏感和准确的微管状。 结果:使用CisaPride作为内标,通过液 - 液萃取从300μl肝素化等离子体中提取CIN,并用阳性多反应监测MS的超优性液相色谱分析。 结论:该方法在50至2000pg / ml的范围内被证明是快速,准确和稳定的,并在药代动力学相互作用试验中成功验证并应用,在那里证明了司石酮的口服共同施用不会改变生物利用度 cin。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号